Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.55 |
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982425 | 0.88 | MCL1 (0.69) | METAP2ALDH1A1MCL1BCL2A1 | |
| SCHEMBL2003387 | 0.83 | METAP2 (0.77) | METAP2KDM4EKDM1A | |
| SCHEMBL12200769 | 0.80 | METAP2 (0.71) | METAP2KDM4EALDH1A1MCL1KDM1A | |
| SCHEMBL3984413 | 0.80 | METAP2 (1.00) | METAP2KDM4EALDH1A1 | |
| SCHEMBL23141205 | 0.78 | KDM1A (0.81) | METAP2KDM4EALDH1A1L3MBTL1KDM1A | |
| SCHEMBL28996025 | 0.77 | ALDH1A1 (0.51) | METAP2ALDH1A1KDM1A | |
| SCHEMBL27770303 | 0.76 | KDM4E (0.68) | METAP2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL20476527 | 0.76 | METAP2 (0.50) | METAP2KDM4EALDH1A1L3MBTL1MCL1 | |
| SCHEMBL31681250 | 0.75 | METAP2 (0.74) | METAP2KDM4EMCL1BCL2A1 | |
| SCHEMBL13034780 | 0.74 | METAP2 (0.62) | METAP2ALDH1A1MCL1BCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885KDM4E 2363/4885ALDH1A1 3463/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885KDM4E 2363/4885ALDH1A1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.